[go: up one dir, main page]

YU21999A - Farmaceutske smese i postupak za njihovo dobijanje - Google Patents

Farmaceutske smese i postupak za njihovo dobijanje

Info

Publication number
YU21999A
YU21999A YU21999A YU21999A YU21999A YU 21999 A YU21999 A YU 21999A YU 21999 A YU21999 A YU 21999A YU 21999 A YU21999 A YU 21999A YU 21999 A YU21999 A YU 21999A
Authority
YU
Yugoslavia
Prior art keywords
procedure
production
pharmaceutical compositions
syldenafile
compositions
Prior art date
Application number
YU21999A
Other languages
English (en)
Inventor
Cristi Bell-Huff
Thomas Francis Dolan
Angela Carol Gatlin Hausberger
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU21999A publication Critical patent/YU21999A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Polymers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Opisane su farmaceutske smese sildenafila koje sadrže slobodnu bazu sildenafila i farmaceutski prihvatljiv nosač koji ima karakteristiku da se brzo topi u ustima. Takođe je opisan postupak za dobijanje tih smesa.[The description refers to the pharmaceutic compositions of syldenafile containing a free base of syldenafile and pharmaceutically acceptable bearer, characterized by being quickly melted in the mouth. Also, a procedure has been described for obtaining such compositions.
YU21999A 1998-05-15 1999-05-13 Farmaceutske smese i postupak za njihovo dobijanje YU21999A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
YU21999A true YU21999A (sh) 2002-03-18

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
YU21999A YU21999A (sh) 1998-05-15 1999-05-13 Farmaceutske smese i postupak za njihovo dobijanje

Country Status (32)

Country Link
US (1) US20020002172A1 (sh)
EP (1) EP0960621A3 (sh)
JP (1) JPH11349483A (sh)
KR (1) KR19990088249A (sh)
CN (1) CN1251758A (sh)
AP (1) AP9901534A0 (sh)
AR (1) AR016481A1 (sh)
AU (1) AU753478B2 (sh)
BG (1) BG103396A (sh)
BR (1) BR9902086A (sh)
CA (1) CA2272042A1 (sh)
CO (1) CO5060503A1 (sh)
DZ (1) DZ2786A1 (sh)
EA (1) EA002830B1 (sh)
GT (1) GT199900061A (sh)
HN (1) HN1999000066A (sh)
HR (1) HRP990144A2 (sh)
HU (1) HUP9901606A2 (sh)
ID (1) ID23299A (sh)
IS (1) IS5046A (sh)
MA (1) MA26629A1 (sh)
NO (1) NO992339L (sh)
NZ (1) NZ335772A (sh)
OA (1) OA11040A (sh)
PA (1) PA8472901A1 (sh)
PE (1) PE20000546A1 (sh)
PL (1) PL333118A1 (sh)
SG (1) SG79255A1 (sh)
SK (1) SK61599A3 (sh)
TR (1) TR199901077A3 (sh)
YU (1) YU21999A (sh)
ZA (1) ZA993338B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
AU3744800A (en) * 1999-03-16 2000-10-04 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
US7501409B2 (en) * 2000-09-06 2009-03-10 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (sh) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
DE50209015D1 (de) * 2001-05-09 2007-02-01 Bayer Healthcare Ag NEUE VERWENDUNG VON 2-Ä2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenylÜ-5-methyl-7-propyl-3H-imidazoÄ5,1-fÜÄ1,2,4Ütriazin-4-on
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
JPWO2003028706A1 (ja) * 2001-09-28 2005-01-13 株式会社三和化学研究所 有核型速溶崩壊性成型品
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
WO2008078730A1 (ja) * 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
BRPI0807281A2 (pt) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Reduzindo os efeitos colaterais de tramadol
EP2167057A1 (en) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde inhibitors for the treatment of hearing impairment
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
US8617588B2 (en) 2009-03-09 2013-12-31 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2338474A1 (de) * 2009-12-23 2011-06-29 Ratiopharm GmbH Oral dispersible Tablette enthaltend kompaktierte Sildenafil-Base
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
CN103402504B (zh) * 2011-02-11 2015-10-14 西梯茜生命工学股份有限公司 包含西地那非游离碱的膜制剂及其生产方法
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
AU3744800A (en) * 1999-03-16 2000-10-04 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration

Also Published As

Publication number Publication date
HUP9901606A2 (en) 2002-09-28
BR9902086A (pt) 2000-05-02
BG103396A (bg) 2000-01-31
DZ2786A1 (fr) 2003-12-01
OA11040A (en) 2003-01-01
AP9901534A0 (en) 1999-06-30
CO5060503A1 (es) 2001-07-30
SG79255A1 (en) 2001-03-20
EA002830B1 (ru) 2002-10-31
EP0960621A2 (en) 1999-12-01
CN1251758A (zh) 2000-05-03
JPH11349483A (ja) 1999-12-21
HU9901606D0 (en) 1999-07-28
AU753478B2 (en) 2002-10-17
ZA993338B (en) 2000-11-14
MA26629A1 (fr) 2004-12-20
EA199900373A3 (ru) 2000-08-28
IS5046A (is) 1999-11-16
ID23299A (id) 2000-04-05
SK61599A3 (en) 2000-12-11
TR199901077A2 (en) 1999-12-21
CA2272042A1 (en) 1999-11-15
PE20000546A1 (es) 2000-07-07
KR19990088249A (ko) 1999-12-27
HN1999000066A (es) 1999-09-29
US20020002172A1 (en) 2002-01-03
PL333118A1 (en) 1999-11-22
NZ335772A (en) 2000-12-22
HRP990144A2 (en) 2000-02-29
NO992339L (no) 1999-11-16
AU2812699A (en) 1999-11-25
AR016481A1 (es) 2001-07-04
EP0960621A3 (en) 2000-01-05
PA8472901A1 (es) 2000-09-29
TR199901077A3 (tr) 1999-12-21
EA199900373A2 (ru) 1999-12-29
GT199900061A (es) 2000-10-14
NO992339D0 (no) 1999-05-14

Similar Documents

Publication Publication Date Title
YU21999A (sh) Farmaceutske smese i postupak za njihovo dobijanje
HUP0001285A3 (en) Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
CA2318128A1 (en) Oral liquid compositions
TW355683B (en) Composition containing micronized nebivolol
HU9402232D0 (en) 1-benzene-sulfonyl-1,3-dihydro-indol-2-one derivatives, process for producing them and pharmaceutical compositions containing them
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
HK1039273A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
HUP0201937A3 (en) Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect
HUP0100760A3 (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives, process for producing them and pharmaceutical compositions containing them
BG103714A (en) Pararacetamol-containing tablet
HUP0301228A3 (en) 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them
HUP0102671A3 (en) Immunosupressive pharmaceutical compositions containing 2',2'-difluoro-nucleoside analogues
CA2318260A1 (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
HK1055947A1 (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1H-Ä1,2,4Ütriazol, methods for producing them and pharmaceutical compositions containing them
TW200517127A (en) Novel composition
HUP0200868A3 (en) Novel 8a- and 9a-15-membered lactams, process for their preparation, pharmaceutical compositions containing them and their use
HU9900263D0 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
GR3034549T3 (en) Anhydrous composition comprising lactulose
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
HUP0004177A3 (en) 4,5-diaryloxazole derivatives, pharmaceutical compositions containing them and process for producing them
HUP0200643A3 (en) Dibenzoazulene derivatives, pharmaceutical compositions containing them, process for producing them and use of them for producing pharmaceutical compositions
HUT58068A (en) Process for producing new, pharmacologically active compounds and pharmaceutical composition comprising same as acvtive ingredient